Aura Biosciences, Inc.

AURA

US05153U1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:03:46 2024-04-29 am EDT			5-day change	1st Jan Change
7.455 ^USD	+3.25%		+4.94%	-16.03%

Apr. 15	Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	CI
Mar. 27	Aura Biosciences Shares Rise Following Q4 Results	MT

Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell 2500 Growth Index

June 23, 2023 at 12:00 am EDT

Latest news about Aura Biosciences, Inc.

Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	Apr. 15	CI
Aura Biosciences Shares Rise Following Q4 Results	Mar. 27	MT
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
BTIG Cuts Aura Biosciences' Price Target to $21 From $38, Keeps Buy Rating	Dec. 08	MT
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	Dec. 08	MT
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	Dec. 07	CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	Nov. 16	DJ
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing	Nov. 09	MT
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Aura Biosciences, Inc. Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-Sar) in Early-Stage Choroidal Melanoma	Nov. 06	CI
Aura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-Sar	Nov. 06	DJ
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023	23-10-31	CI
Aura Biosciences Insider Bought Shares Worth $168,175, According to a Recent SEC Filing	23-10-06	MT
Aura Biosciences Appoints New Chief Medical Officer	23-10-02	MT
Aura Biosciences, Inc. Announces Executive Changes	23-10-02	CI
Aura Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Scotiabank Starts Aura Biosciences at Sector Outperform With $23 Price Target	23-07-27	MT
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell Small Cap Comp Value Index	23-06-23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell Microcap Value Index	23-06-23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell 3000E Value Index	23-06-23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell 2500 Value Index	23-06-23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell 3000 Value Index	23-06-23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) added to Russell 2000 Value Index	23-06-23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell Microcap Growth Index	23-06-23	CI
Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell 3000E Growth Index	23-06-23	CI

Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.22 USD

Average target price

19.8 USD

Spread / Average Target

+174.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AURA BIOSCIENCES, INC.	-16.03%	358M
IQVIA HOLDINGS INC.	+2.12%	42.75B
LONZA GROUP AG	+47.58%	41.61B
MODERNA, INC.	+11.32%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.11%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.77%	18.12B
MEDPACE HOLDINGS, INC.	+29.58%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.99%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.04%	11B

Other Biotechnology & Medical Research